Fused antrum stage

Across TCGA pan-cancer cohorts, RNA activity of the Fused antrum stage pathway differs between tumor and matched normal tissue in 10 of the 18 cancer types tested.

The strongest signal is observed in stomach adenocarcinoma (STAD), where pathway activity is lower in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as STAD and BLCA, show the opposite pattern, with lower activity in tumor tissue.

STAD, KICH, and LIHC show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
STAD	All	II,III,IV	−0.105	.002	7	view →
KICH	Male	II,III,IV	+0.118	.004	6	view →
LIHC	Male	All	+0.119	<.001	5	view →
KIRC	Male	II,III,IV	+0.039	.017	4	view →
BLCA	All	All	−0.068	.013	3	view →
CHOL	All	All	+0.103	.016	2	view →
HNSC	Female	III,IV	+0.079	.002	2	view →
PRAD	All	All	−0.044	.004	2	view →
THCA	Male	All	−0.040	.022	1	view →
LUAD	All	All	−0.036	.010	1	view →

Pink = more active in tumor, green = less active in tumor. Showing the 10 strongest of 10 lineages.

GO:0048165–STAD

Open the STAD breakdown →